1. A method of treating a human individual having multiple myeloma, comprising: administering isatuximab to the individual at a weekly dose of 10 mg/kg of a first one-month cycle; administering the isatuximab at a dose of 10 mg/kg once every two weeks of a one-month cycle for at lea...
In relapsed and refractory multiple myeloma (RRMM), there are few treatment options once patients progress from the established standard of care. Several bispecific T-cell engagers (TCE) are in clinical development for multiple myeloma (MM), designed to promote T-cell activation and tumor killing ...
(mAb) approved for use in the treat- ment of adults with multiple myeloma (MM): in combination with pomalidomide and dexamethasone for those with relapsed and refractory MM (RRMM) who have received ≥ 2 prior therapies, including lenalidomide and a proteasome inhibitor; and in combination ...
Immunomodulatory drugs (IMiDs) have become an integral part of therapy for both newly diagnosed and relapsed/refractory multiple myeloma (RRMM). IMiDs bind to cereblon, leading to the degradation of proteins involved in B-cell survival and proliferation. Thalidomide, a first-generation IMiD, has lit...
Multiple myeloma (MM) is a common haematological malignancy characterized by clonal expansion of transformed plasma cells in the bone marrow and increased production of monoclonal (M)-protein (nonfunctional intact immunoglobulins or immunoglobulin chains) [1,2]. It is associated with substantial morbidit...
Detection and characterization of syndecan-1-associated heparan sulfate 6-O-sulfated motifs overexpressed in multiple myeloma cells using single chain antibody variable fragments. Hum. Antibodies 2012, 21, 29–40. [CrossRef] 40. Blackhall, F.H.; Merry, C.L.; Davies, E.J.; Jayson, G.C. ...